ATE454140T1 - Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität - Google Patents

Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität

Info

Publication number
ATE454140T1
ATE454140T1 AT05732660T AT05732660T ATE454140T1 AT E454140 T1 ATE454140 T1 AT E454140T1 AT 05732660 T AT05732660 T AT 05732660T AT 05732660 T AT05732660 T AT 05732660T AT E454140 T1 ATE454140 T1 AT E454140T1
Authority
AT
Austria
Prior art keywords
optically pure
dopamine agonist
preferred
sedative agent
desmethylzopiclone
Prior art date
Application number
AT05732660T
Other languages
English (en)
Inventor
Timothy Barberich
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of ATE454140T1 publication Critical patent/ATE454140T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05732660T 2004-02-18 2005-02-07 Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität ATE454140T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54541304P 2004-02-18 2004-02-18
PCT/US2005/003937 WO2005079851A2 (en) 2004-02-18 2005-02-07 Dopamine-agonist combination therapy with sedatives for improving sleep quality

Publications (1)

Publication Number Publication Date
ATE454140T1 true ATE454140T1 (de) 2010-01-15

Family

ID=34886149

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05732660T ATE454140T1 (de) 2004-02-18 2005-02-07 Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität

Country Status (10)

Country Link
US (2) US20050267176A1 (de)
EP (1) EP1742624B1 (de)
JP (1) JP2007523165A (de)
AT (1) ATE454140T1 (de)
AU (2) AU2005215376B2 (de)
CA (1) CA2556870C (de)
DE (1) DE602005018763D1 (de)
DK (1) DK1742624T3 (de)
ES (1) ES2337700T3 (de)
WO (1) WO2005079851A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
ATE454140T1 (de) 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
CA2557850A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
EP1844047A1 (de) * 2004-10-18 2007-10-17 Neurocrine Biosciences, Inc. Hydrat von n-methyl-n-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamid und verfahren zur herstellung davon
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
JP2008543953A (ja) * 2006-04-20 2008-12-04 テバ ファーマシューティカル インダストリーズ リミティド エスゾピクロン結晶形態ａ、実質的に純粋なエスゾピクロン及び光学的に豊富なエスゾピクロンを調製するための方法
US20080045547A1 (en) * 2006-07-07 2008-02-21 Lippa Arnold S Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
EP1987815A1 (de) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Im Mund-Nasen-Rachenraum verabreichbare pharmazeutische Zusammensetzungen enthaltend Dopaminagonisten zur Vorbeugung und/oder Behandlung von unruhigen Gliedmassen
US20080299189A1 (en) * 2007-06-04 2008-12-04 Drugtech Corporation Controlled release dopamine agonist compositions
EP2020403A1 (de) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Verfahren zur Auflösung von Zopiclon und Zwischenprodukten
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN102395595A (zh) * 2008-11-06 2012-03-28 生物链接治疗股份有限公司 不宁腿综合症和睡眠障碍的治疗
MX353752B (es) 2009-01-20 2018-01-26 Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct Los ácidos sórbico y benzoico y sus derivados aumentan la actividad de un neurofármaco.
AU2010208240A1 (en) 2009-01-30 2011-09-22 Sunovion Pharmaceuticals Inc Coated tablets of 6-(5-chloro-2-pyridyl) -5-[ (4-methyl-1-piperazinyl) carbonyloxy]-7-oxo-6, 7-dihydro-5H-pyrrol o [3,4-b] pyrazine and methods for measuring effectiveness of coating
JP5885668B2 (ja) 2009-12-02 2016-03-15 アダマス ファーマシューティカルズ， インコーポレイテッド アマンタジン組成物および使用方法
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (de) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermale zusammensetzungen mit einer wirkstoffschicht und einer wirkstoffumwandlungsschicht
EP2776020B1 (de) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Verfahren zur behandlung von neoplasmen der haut
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
AU2016304737B2 (en) * 2015-08-11 2021-03-11 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
CA3027300C (en) 2016-06-13 2023-08-08 Syneurx International (Taiwan) Corp. Co-crystals of lithium benzoate and uses thereof
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
WO2018042352A1 (en) * 2016-08-31 2018-03-08 Taro Pharmaceutical Industries Fenoldopam topical formulations for treating skin disorders
CA3072764A1 (en) 2017-08-24 2019-02-28 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
NZ781774A (en) 2019-03-08 2023-03-31 Taro Pharma Ind Stable topical compositions of fenoldopam
JP2022532851A (ja) * 2019-04-22 2022-07-20 エル クノブラー、ロバート ホットフラッシュの非ホルモン治療

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) * 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
FR2492382A1 (fr) 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US4505029A (en) * 1981-03-23 1985-03-19 General Electric Company Semiconductor device with built-up low resistance contact
US4419345A (en) * 1981-07-20 1983-12-06 Kinetic Systems, Inc. Sleep-inducing pharmaceutical composition and method
DE3228351C2 (de) * 1982-07-29 1985-07-25 Merckle GmbH, 7902 Blaubeuren Arzneimittel zur Behandlung von Schlafstörungen
US4654347A (en) 1983-06-23 1987-03-31 American Cyanamid Company Aryl and heteroaryl[[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanones
US4626538A (en) 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
FR2606410B1 (fr) 1986-11-07 1989-02-24 Synthelabo Imidazopyridines, leur preparation et leur application en therapeutique
US5017616A (en) * 1989-11-30 1991-05-21 Jeffrey Askanazi Method for improving ventilation during sleep and treating sleep related ventilation abnormalities
FR2671800B1 (fr) * 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
US5786357A (en) 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US5538977A (en) 1995-03-17 1996-07-23 American Cyanamid Company 3-Substituted-7-[3-(imidazol-1-yl)phenyl]-pyrazolo[1,5-a]pyrimidines
IT1276522B1 (it) 1995-04-07 1997-10-31 Elena Benincasa Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
US5714607A (en) 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
IL131670A (en) * 1997-03-12 2005-07-25 Addex Pharmaceuticals Sa Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
US6348485B1 (en) * 1998-06-09 2002-02-19 Takeda Chemical Industries, Ltd. Method for treating or preventing sleep disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) * 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
SE9803760D0 (sv) * 1998-11-04 1998-11-04 Jan Hedner Sätt att behandla och diagnostisera syndromet restless legs och motsvarande medel
EP1005863A1 (de) 1998-12-04 2000-06-07 Synthelabo Dosisformen mit gesteuerter Wirkstofffreigabe enthaltend ein kurzer wirkung Hypnotikum oder einem Salz davon
HUP0200501A3 (en) 1999-03-19 2004-03-29 Abbott Gmbh & Co Kg Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
US6339086B1 (en) * 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
US6231594B1 (en) * 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
US20030087963A1 (en) * 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
AU2003285012A1 (en) * 2002-10-24 2004-05-13 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
EP1641456B1 (de) 2003-06-25 2010-03-03 H. Lundbeck A/S Gaboxadol zur behandlung von depressionen und anderen affektiven störungen
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
US20050228052A1 (en) * 2004-01-29 2005-10-13 Barberich Timothy J Methods of treating, preventing and managing a sleep disorder using (S)-didesmethylsibutramine
ATE454140T1 (de) 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
US7465729B2 (en) * 2004-04-05 2008-12-16 Sepracor Inc. Methods of treatment of menopause and perimenopause using eszopiclone
CA2557850A1 (en) * 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
CN101257907A (zh) 2005-07-06 2008-09-03 塞普拉科公司 左旋佐匹克隆和抗抑郁剂的组合
EP1904046A4 (de) 2005-07-06 2008-10-01 Sepracor Inc Kombinationen von eszopiclon und o-desmethylvenlafaxin und verfahren zur behandlung der menopause und von stimmungsschwankungen; angstzuständen und kognitiven störungen
WO2007005940A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
WO2007006003A2 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Also Published As

Publication number Publication date
US20050267176A1 (en) 2005-12-01
AU2005215376B2 (en) 2011-01-20
CA2556870A1 (en) 2005-09-01
EP1742624A2 (de) 2007-01-17
AU2005215376A1 (en) 2005-09-01
ES2337700T3 (es) 2010-04-28
US20100004251A1 (en) 2010-01-07
DK1742624T3 (da) 2010-03-08
CA2556870C (en) 2014-01-28
WO2005079851A2 (en) 2005-09-01
JP2007523165A (ja) 2007-08-16
DE602005018763D1 (de) 2010-02-25
WO2005079851A3 (en) 2006-06-22
AU2011201703A1 (en) 2011-05-12
EP1742624B1 (de) 2010-01-06
US8877755B2 (en) 2014-11-04

Similar Documents

Publication Publication Date Title
DE602005018763D1 (de) Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
WO2005063297A3 (en) Melatonin combination therapy for improving sleep quality
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
CL2008001932A1 (es) Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer.
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
MX358618B (es) Usos de inhibidores de dpp iv.
MX2009013989A (es) Terapia en combinacion para depresion.
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
EP2331095A4 (de) Bestimmte kynurenin-3-monooxygenase-inhibitoren, pharmazeutische zusammensetzungen und anwendungsverfahren dafür
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
DE602006021444D1 (de) Therapie zur behandlung der überaktiven blase
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA200901339A1 (ru) Ороназофарингеально доставляемая фармацевтическая композиция агонистов дофамина для предупреждения/облегчения и/или лечения расстройств беспокойных конечностей
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
EP1543158A4 (de) Regulierte aptamer-therapeutika
TW200501948A (en) Composition for improving cognition and memory
ATE410163T1 (de) Verfahren zur behandlung und diagnose von atemstörungen im schlaf mit zonisamid und mittel zur durchführung des verfahrens
NO20073104L (no) Anvendelse av en 5-HT6 agonist for behandling og forebygging av neurodegenerative forstyrrelser
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
WO2009131850A3 (en) Pai-1 expression and activity inhibitors for the treatment of ocular disorders
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
DE602004016547D1 (de) 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties